Syndax, Genentech to Test Combo Therapy for HR-positive, HER2-negative Metastatic Breast Cancer

Syndax, Genentech to Test Combo Therapy for HR-positive, HER2-negative Metastatic Breast Cancer
An upcoming Phase 1b/2 trial will evaluate Syndax Pharmaceuticals‘ investigational therapy entinostat in combination with Genentech‘s Tecentriq (atezolizumab) in women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have received one previous line of therapy. The trial is part of a new clinical collaboration between the two companies.

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *